erythropoietin   Click here for help

GtoPdb Ligand ID: 4921

Synonyms: Epogen® | Procrit®
Approved drug
erythropoietin is an approved drug (FDA (no history prior to 1989 available))
Comment: Recombinant forms of human erythropoietin (epoetins), are contained in various approved drugs with INNs that reflect the different glycoform structures formed by different manufacturing processes. The table below provides details of the epoetin alpha originator drug and biosimilars that are currently approved for use by the US FDA and/or the European Medicines Agency (EMA).

Epoetin alpha and biosimilar drugs.

INNTrade names (authorisation holder)First FDA approvalFirst EMA approval
epoetin alfaBinocrit (Sandoz), Abseamed (Medice Arzneimittel Pütter), Epogen (Amgen), Procrit (Janssen)19892007
epoetin betaNeoRecormon, Recormon (both Roche)n/a1997
epoetin zeta (a.k.a. epoetin alfa-epbx)Silapo (Stada Arzneimitte), Retacrit (Hospira)20182007
epoetin thetaBiopoin (Teva), Eporatio (Ratiopharm)n/a2009
Species: Human
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: erythropoietin

No information available.
Summary of Clinical Use Click here for help
Epoetin alfa is used to treat anemia caused by chemotherapy, chronic kidney disease, or as a result of taking zidovudine to treat HIV. It may also be used before and after surgical procedures where blood loss would indicate the need for red blood cell transfusion.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Binding of erythropoietin to the erythropoietin receptor activates the JAK-STAT signaling pathway, which in turn results in the activation of transcription factors that control red blood cell formation.